Interestingly, cellular chemosensitivity towards doxorubicin and paclitaxel was increased when survivin was targeted by miR-485-5p, while cisplatin resistance was claimed to be attributed to PI3K/Akt signaling targeted by miR-485-5p in ovarian cancer [64, 67]. This evidence concerns the gene AKT1 and ovarian carcinoma.